Recent machine-extracted executive movements from SEC 8-K Item 5.02 filings, source-linked. Every card cites the SEC source.
Showing 1501–1550 of 18397
On April 21, 2025, Timothy J. Murphy notified Repay Holdings Corporation (the “Company”) of his decision to resign as Chief Financial Officer of the Company, effective May 15, 2025.
As previously announced, on February 13, 2025 the Board appointed John D. Calys, the Company’s Senior Vice President, Global Controller and Chief Accounting Officer, to succeed its current Chief Financial Officer, George Kilguss, upon his retirement on May 31, 2025.
As previously announced, on February 13, 2025 the Board appointed John D. Calys, the Company’s Senior Vice President, Global Controller and Chief Accounting Officer, to succeed its current Chief Financial Officer, George Kilguss, upon his retirement on May 31, 2025.
Nathan Bennett, who served as the Company's Chief Accounting Officer/Interim Chief Financial Officer from January 1, 2024 to April 21, 2025, was appointed as Chief Financial Officer of the Company effective April 21, 2025.
On April 22, 2025, Michael J. Rugen resigned as the Chief Financial Officer of New Era Helium, Inc. (the “ Company ”) with an effective date of May 31, 2025 (the “ Effective Date ”).
In connection with the Merger, as of the Effective Time, Shai Terem resigned from his role as Chief Executive Officer and President of the Company
On April 24, 2025, Assaf Zipori informed the Board of Directors of the Company (the “Board”) that he would resign from his position as Chief Financial Officer, Treasurer and Secretary of the Company, effective immediately
On April 21, 2025, the Company announced the appointment of Kurt Keller as the chief financial officer (CFO) of the Company.
On April 22, 2025, Mr. Bernard Birkett notified West Pharmaceutical Services, Inc. (the “Company”) of his intention to retire as Senior Vice President & Chief Financial Officer later this year.
announced the appointment of David A. Pace to the position of President and Chief Executive Officer (“President and CEO”) of the Company, effective April 24, 2025
Mr. Pace replaces G.J. Hart as the Company’s President and CEO, who will also depart from the Board of Directors (the “Board”) of the Company as of the Effective Date.
Further, on April 24, 2025, the Partnership announced the expansion of responsibilities for Andrew Miedler, the Partnership’s Chief Financial Officer. Effective as of June 1, 2025, Mr. Miedler will assume responsibility for digital and data and will continue in his role as the Partnership’s principal financial officer.
Mr. Dziedzic will retire as President and CEO and step down from the Board, effective October 24, 2025.
the Board also appointed Payman Khales, the Company’s current Chief Operating Officer, to succeed Mr. Dziedzic as President and CEO
On April 23, 2025, the Company’s Board of Directors elected Howard Jonas, the Company’s Executive Chairman and Chairman of the Board, as the Company’s Chief Executive Officer and President, effective June 1, 2025.
On April 23, 2025, William Conkling resigned as Chief Executive Officer and President of Rafael Holdings, Inc. (the “Company”), effective May 31, 2025.
On April 24, 2025, the Board of Directors of Healthpeak Properties, Inc. (the “Company”) appointed Kelvin O. Moses as the Company’s Chief Financial Officer and principal financial officer, effective immediately, pursuant to the Company’s succession plan.
Mr. Balu’s decision to resign is not the result of any dispute or disagreement with the Company, the Company’s management or the Company’s Board of Directors on any matter relating to the Company’s operations, policies or practices.
On April 22, 2025, the Board of Directors of Wellgistics Health, Inc. (the “Company”) appointed Mark DiSiena as Chief Financial Officer of the Company, effective as of April 22, 2025
Jonathan Monson, who currently serves as Senior Vice President, Investor Relations, has been promoted to Executive Vice President and Chief Financial Officer of the Company effective as of June 30, 2025
On April 23, 2025, Boston Scientific Corporation (the “Company”) announced that Daniel J. Brennan has decided to retire from his role as Executive Vice President and Chief Financial Officer of the Company effective as of June 29, 2025
On the Effective Date, Mr. Kutsor will succeed Dave Rawden from AlixPartners LLP, a leading global business advisory firm, who has served as the Company’s Interim Chief Financial Officer since November 20, 2024.
On April 23, 2025, Evolv Technologies Holdings, Inc. (the “Company”) announced that the Board of Directors of the Company (the “Board”) appointed George C. Kutsor as the Company’s new Chief Financial Officer on April 21, 2025, to be effective one business day following the filing of the Company’s annual report on Form 10-K for the fiscal year ended December 31, 2024 (the “Effective Date”).
Charles Todd, Jr.. (the “Executive”), who, in conjunction with the execution the Employment Agreement, was appointed as the Company’s Chief Executive Officer
On April 17, 2025, the Company’s board of directors (the “Board”) appointed Ms. Chenyang Wang as the Company’s acting chief financial officer, with effect from April 18, 2025.
On April 18, 2025, Mr. Jing Jin, the chief financial officer of Greenland Technologies Holding Corporation, a business company formed in the British Virgin Islands (the “Company”), resigned as the chief financial officer of the Company, effective April 18, 2025.
On April 17, 2025, John (Fei) Han was appointed as the Chief Financial Officer of the Defi Development Corp., formerly known as Janover Inc. (the “ Company ”).
In connection with Mr. Han’s appointment as the Chief Financial Officer of the Company, Mr. Rosenbloom stepped down as the Chief Financial Officer of the Company, effective immediately.
The reappointment follows Mike Nelson’s departure from the role of Chief Executive Officer
On April 18, 2025 the Board of Directors of Basanite, Inc. (the “Company”) approved the reappointment of Ronald LoRicco, Sr. as the Company’s Acting Interim Chief Executive Officer, effective immediately.
On April 17, 2025, Adagio Medical Holdings, Inc. (the “Company”) appointed Daniel George as the Company’s Interim Chief Financial Officer and designated Mr. George as its principal financial officer and principal accounting officer.
On April 21, 2025, Eyal Rubin, Sr. Vice President and Chief Financial Officer of Protalix BioTherapeutics, Inc., a Delaware corporation (the “Company”), provided the Company and the Company’s Board of Directors with six months’ notice of his resignation from his position with the Company and its subsidiary, in order to pursue other opportunities.
Also, effective April 22, 2025, the Company has named Frank DeMaria (36) as Chief Financial Officer of the Company.
the Board, by a unanimous vote, appointed Eric Poma, Ph.D. to serve as CEO of the Company, effective April 22, 2025.
Allan Camaisa notified the board of directors (“Board”) of Calidi Biotherapeutics, Inc. (the “Company”) of his resignation as the Company’s Chief Executive Officer (“CEO”) and as Chairman of the Board
On April 21, 2025, the Board appointed Mr. Xiaohua Lu as the Chief Executive Officer of the Company.
On April 21, 2025, the Board of Directors (the “Board”) of Nova LifeStyle, Inc. (the “Company”) received a resignation letter from Ms. Thanh H. Lam to resign from her positions as the Chief Executive Officer (“CEO”) and President of the Company, effective immediately.
On April 17, 2025, Dominic L. Hunter, age 62, commenced employment as Chief Financial Officer of the Company.
In connection with this transition, the Company appointed Eric A. Mendelson and Victor H. Mendelson to serve as Co-Chief Executive Officers (co-principal executive officers), also effective May 1, 2025.
In connection with this transition, the Company appointed Eric A. Mendelson and Victor H. Mendelson to serve as Co-Chief Executive Officers (co-principal executive officers), also effective May 1, 2025.
Robert Rajalingam was appointed as the new Chief Executive Officer of the Company effective April 17, 2025.
Donald Zurbay, who previously served as Chief Executive Officer and a director of the Company, ceased to serve in such roles effective the same day.
Thomas Langan, the Company’s Interim Chief Executive Officer, President and Chief Commercial Officer, entered into a Separation Agreement (the “Langan Separation Agreement”), pursuant to which Mr. Langan’s employment with the Company will terminate effective July 31, 2025
On April 22, 2025, the Board of Directors (“Board”) of OPENLANE, Inc. (the “Company”) appointed Bradley Herring as Executive Vice President and Chief Financial Officer of the Company, effective May 27, 2025.
designated Michael D. Hays, the Company’s Chief Executive Officer, to serve as the Company’s principal financial officer.
On April 22, 2025, Weatherford International plc (the “Company”) announced the appointment of Anuj Dhruv, 43, to serve as the Company’s Executive Vice President and Chief Financial Officer, effective April 21, 2025.
In conjunction with the appointment of Mr. Dhruv, Arunava Mitra has left Weatherford effective April 21, 2025 and has ceased to serve as its Executive Vice President and Chief Financial Officer.
Effective May 1, 2025, Stephen D. Young, after 24 years of service, will step down from his role as the Company’s Chief Financial Officer (CFO).
Effective May 1, 2025, Jessica Betjemann will begin service as an Executive Vice President and the Company’s CFO.
On April 17, 2025, Chadi Chahine delivered a letter of resignation to the Company and Parent to notify the Company and Parent of his decision to resign as Chief Financial Officer and EVP of Supply Chain Operations of the Company, effective upon the consummation of the Merger.
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.